Publicacións en colaboración con investigadores/as de Charité (7)

2024

  1. Safety of 300IR house dust mite sublingual tablet from pooled clinical trial and post-marketing data

    World Allergy Organization Journal , Vol. 17, Núm. 7

2021

  1. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial

    Journal of Allergy and Clinical Immunology, Vol. 147, Núm. 3, pp. 1020-1030.e10

  2. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 4, pp. 1041-1052

  3. Placebo effects in allergen immunotherapy—An EAACI Task Force Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 629-647

2018

  1. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, Núm. 4, pp. 827-836

2016

  1. Allergy immunotherapy across the life cycle to promote active and healthy ageing: From research to policies

    Clinical and Translational Allergy, Vol. 6, Núm. 1

2012

  1. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

    Clinical and Translational Allergy, Vol. 2, Núm. 1